We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Q4 Earnings Beat Estimates, Rise Y/Y
Read MoreHide Full Article
Cardinal Health Inc. (CAH - Free Report) reported fourth-quarter fiscal 2017 adjusted earnings of $1.31 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 14.9% on a year-over-year basis.
Revenues increased 5% on a year-over-year basis to almost $33 billion, beating the Zacks Consensus Estimate of $32.8 billion.
Quarter Details
Pharmaceutical Segment: Pharmaceutical revenues rose 5% to $29.6 billion on a year-over-year basis. The segment witnessed strong growth in the Specialty business and also gained a huge number of Pharmaceutical Distribution customers.
However, generic pharmaceutical pricing and the company's recent investments in its Pharmaceutical IT platform led to a 7% drop in segmental profits. However, solid performance by the Red Oak Sourcing platform has partially offset the negative effect.
Medical Segment: Revenues at the segment increased 9% to $3.4 billion primarily on higher contributions from new and existing customers.
Medical segment profits increased 13% to $138 million, courtesy of higher contributions from new and existing customers and solid performance by the post-acute segment. However, unfavorable performances by Cardinal Health Branded products (including Cordis) partially offset sales at the segment.
Other Details: Distribution, selling, general and administrative (SG&A) expenses increased 3% on a year-over-year basis to $377 million in the reported quarter. Cash and equivalents were $6879 million as of Jun 30, 2017.
For fiscal 2017, Cardinal Health registered adjusted earnings of $5.40 per share, up 3% on a year-over-year basis. Revenues increased 7% on a year-over-year basis to a record $130 billion.
Delving deeper into the segmental revenue details, Pharmaceutical segment (89.6% of net revenues) increased 7% to $116.5 billion in fiscal 2017. Medical segment (10.4% of net revenues) revenues soared 95% on a year-over-year basis to $13.5 billion.
Guidance
The company issued fiscal 2018 guidance for adjusted earnings per share from continuing operations of $4.85–$5.10. Furthermore, Cardinal Health is expected to register fiscal 2019 adjusted earnings per share of at least $5.60.
Key Picks
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corporation (EW - Free Report) , Abiomed Inc. and Fresenius Medical Care Corporation (FMS - Free Report) .
Fresenius Medical Care represents a return of 2.5% over the last one year. The company delivered a solid earnings surprise of 20.5% in the last reported quarter.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock has a one-year return of 1.5%.
Abiomed yielded a strong return of 23.4% over the last one year. The stock has a long-term expected earnings growth rate of 30.5%.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential.See these stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardinal Health (CAH) Q4 Earnings Beat Estimates, Rise Y/Y
Cardinal Health Inc. (CAH - Free Report) reported fourth-quarter fiscal 2017 adjusted earnings of $1.31 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 14.9% on a year-over-year basis.
Revenues increased 5% on a year-over-year basis to almost $33 billion, beating the Zacks Consensus Estimate of $32.8 billion.
Quarter Details
Pharmaceutical Segment: Pharmaceutical revenues rose 5% to $29.6 billion on a year-over-year basis. The segment witnessed strong growth in the Specialty business and also gained a huge number of Pharmaceutical Distribution customers.
However, generic pharmaceutical pricing and the company's recent investments in its Pharmaceutical IT platform led to a 7% drop in segmental profits. However, solid performance by the Red Oak Sourcing platform has partially offset the negative effect.
Medical Segment: Revenues at the segment increased 9% to $3.4 billion primarily on higher contributions from new and existing customers.
Medical segment profits increased 13% to $138 million, courtesy of higher contributions from new and existing customers and solid performance by the post-acute segment. However, unfavorable performances by Cardinal Health Branded products (including Cordis) partially offset sales at the segment.
Other Details: Distribution, selling, general and administrative (SG&A) expenses increased 3% on a year-over-year basis to $377 million in the reported quarter. Cash and equivalents were $6879 million as of Jun 30, 2017.
Cardinal Health, Inc. Price and Consensus
Cardinal Health, Inc. Price and Consensus | Cardinal Health, Inc. Quote
FY17 Highlights
For fiscal 2017, Cardinal Health registered adjusted earnings of $5.40 per share, up 3% on a year-over-year basis. Revenues increased 7% on a year-over-year basis to a record $130 billion.
Delving deeper into the segmental revenue details, Pharmaceutical segment (89.6% of net revenues) increased 7% to $116.5 billion in fiscal 2017. Medical segment (10.4% of net revenues) revenues soared 95% on a year-over-year basis to $13.5 billion.
Guidance
The company issued fiscal 2018 guidance for adjusted earnings per share from continuing operations of $4.85–$5.10. Furthermore, Cardinal Health is expected to register fiscal 2019 adjusted earnings per share of at least $5.60.
Key Picks
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corporation (EW - Free Report) , Abiomed Inc. and Fresenius Medical Care Corporation (FMS - Free Report) .
Notably, Fresenius Medical Care and Edwards Lifesciences sport a Zacks Rank #1 (Strong Buy), while Abiomed has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Fresenius Medical Care represents a return of 2.5% over the last one year. The company delivered a solid earnings surprise of 20.5% in the last reported quarter.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock has a one-year return of 1.5%.
Abiomed yielded a strong return of 23.4% over the last one year. The stock has a long-term expected earnings growth rate of 30.5%.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>